Isomorphic Labs Enters Research Collaboration with Johnson & Johnson to Advance AI-Driven Drug Discovery
Wednesday, January 21, 2026
Isomorphic Labs has entered into a cross-modality, multi-target research collaboration with Johnson & Johnson. The partnership brings together Isomorphic Labs’ AI-first drug discovery approach with Johnson & Johnson’s strengths in drug discovery and development.
Under the agreement, Isomorphic Labs will focus on in silico prediction and drug design, while Johnson & Johnson will carry out experimental testing and take responsibility for advancing selected programmes.
The collaboration will use Isomorphic Labs’ drug design engine, which can generate candidates for complex targets across multiple modalities. These include small molecules, antibodies, peptides, molecular glues, and biologics. This multi-modality capability is expected to support the discovery of new therapeutic options across a range of disease areas.
Isomorphic Labs develops predictive and generative models of biological systems to design novel molecules that may not be identified using traditional methods. Its AI-driven platform aims to improve understanding of disease biology and enable more precise and efficient design of potential drug candidates.
Source: jnjinnovation.com
